HBT-708

N/A

Report date: 2026/02/03 10:43:14

Base Information

Drug NameHBT-708
Drug Alias NameHBT-708SSGJ-708
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-PD-1Anti-TGF-β
TargetsProgrammed cell death protein 1Transforming growth factor beta
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesDansheng Pharmaceutical Technology (Shanghai) Co LtdShenyang Sunshine Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A